↓ Skip to main content

Dove Medical Press

Article Metrics

Role of oral teriflunomide in the management of multiple sclerosis

Overview of attention for article published in Neuropsychiatric Disease and Treatment, April 2013
Altmetric Badge

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
27 Mendeley
Title
Role of oral teriflunomide in the management of multiple sclerosis
Published in
Neuropsychiatric Disease and Treatment, April 2013
DOI 10.2147/ndt.s31248
Pubmed ID
Authors

Cris Constantinescu, Tanasescu, Evangelou

Abstract

The landscape of the treatment of relapsing-remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in relapsing-remitting multiple sclerosis, while others have completed Phase III trials and are awaiting review for registration. Teriflunomide is a pyrimidine synthesis inhibitor with selective immunomodulatory and immunosuppressive properties that have shown consistent efficacy in clinical trials, and a good safety profile. This paper provides an overview of the mechanisms of action and efficacy and safety results from clinical trials with this drug. The role of teriflunomide in the treatment of relapsing-remitting multiple sclerosis is discussed.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 4%
United States 1 4%
Unknown 25 93%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 4 15%
Other 4 15%
Professor > Associate Professor 3 11%
Student > Master 3 11%
Student > Bachelor 2 7%
Other 8 30%
Unknown 3 11%
Readers by discipline Count As %
Medicine and Dentistry 10 37%
Neuroscience 4 15%
Agricultural and Biological Sciences 3 11%
Chemistry 2 7%
Immunology and Microbiology 1 4%
Other 3 11%
Unknown 4 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 May 2013.
All research outputs
#3,076,454
of 4,507,280 outputs
Outputs from Neuropsychiatric Disease and Treatment
#703
of 908 outputs
Outputs of similar age
#59,981
of 88,657 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#38
of 57 outputs
Altmetric has tracked 4,507,280 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 908 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 88,657 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.